MSD in India announces leadership change: KG Ananthakrishnan, Managing Director to retire and Vivek Vasudev Kamath to assume role of Managing Director

5 Dariya News

Bangalore 16-Dec-2016

MSD in India today announced leadership change. K. G. Ananthakrishnan (KG) current Managing Director of MSD in India will retire in the beginning of 2017 and Vivek Vasudev Kamath will assume role of Managing Director Designate from December 16, 2016. MSD in India operates its business in India through three legal entities, MSD Pharmaceuticals Private Limited, Organon (India) Private Limited, and Fulford (India) Limited.Vivek joined MSD in India in July 2012 and is currently the Business Unit Director for Cardiovascular Metabolics and Market Access. KG and Vivek will work together to ensure smooth transition of business responsibilities.Announcing the leadership change, Jan Van Acker, President Asia Pacific Region, MSD said, “I thank KG for his leadership and his contributions to MSD over the past ten years and congratulate Vivek on assuming the role of Managing Director of MSD in India. MSD has a robust succession planning process through which Vivek was identified to lead MSD in India and to deliver on our commitment to patients and communities in the Country. He has successfully led our Cardiovascular Metabolics and Market Access businesses and has fostered collaborative relationships with our customers and business partners, while delivering strong growth”. Vivek Vasudev Kamath has over twenty five years of experience across India, South Asia & ASEAN markets. He brings rich experience with leading Indian and Multinational healthcare organizations in marketing, sales and general management. He has managed portfolios in prescription, over-the counter (OTC) & Diagnostics segments, partnering with healthcare professionals, consumers, diverse trade channels & Government/ non-Government healthcare entities.

About MSD

For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.In India, MSD operates through three separate legal entities: MSD Pharmaceuticals Private Limited, Organon (India) Private Limited, and Fulford (India) Limited. Since its existence in the region, the company has moved quickly in laying the foundation for a business that is differentiated by its focus through launching innovative products relevant to India region. MSD in India is committed to the cause of reducing maternal mortality - with its already functional ‘MSD for Mothers’ program, the company brings extensive technical and technological expertise for creating and implementing relevant interventions from its existing programs in India, Uganda, Senegal, Zambia, and the US.